Maine

The Maine Health Data Organization published its 340B report of April 2, 2026, as Maine's law requires. It covers fiscal year 2024 and adds together what 27 hospitals sent. It prints no figure for any single hospital, so no figure here belongs to one.

Four totals

The report's summary, headed "340B Drug Acquisition Costs and Estimated Savings", gives these four figures for all 27 hospitals together. The two dollar totals are rounded in the report to a tenth of a million, and they are shown here as the report prints them.

A total of 27 hospitals submitted 340B Drug Program data sets to the MHDO for fiscal year 2024 per the requirements in 90-590 Chapter 340, Uniform Reporting System for Reporting 340B Drug Program Data Sets.

In total, these hospitals reported spending $409.9M to acquire prescription drugs under the 340B Drug Program, representing 60.0% of the total amount spent for all drugs by the hospitals (included those purchased under 340B).

The hospitals also reported an estimated savings of $325.8M resulting from 340B discounted drug acquisition costs.

The three sentences the report prints these figures in, word for word. Open the page (Page 3 of the report PDF)

Below the totals the report lists drugs, in two tables. Each hospital named its three most costly drugs and its three most frequently dispensed drugs. A drug is in a table when at least one hospital named it, and the figures beside it are the report's totals for that drug's NDC. The last column is the number of hospitals that named the drug.

Most costly drugs

The report's title for this table is "Top 3 Most Costly 340B Prescription Drugs". It lists 37 drugs on pages 5 to 6 of the report.

The total amount spent across each of the 27 hospitals’ top 3 most costly prescription drugs purchased under the 340B Drug Program represented 15.6% of the total 340B hospital drug acquisition costs.

The sentence the report prints above the table, word for word. Open the page (Page 5 of the report PDF)
Values Reported for Top 3 Most Costly Drugs Acquired Under Hospitals’ 340B Drug Program: 37 drugs as printed
Drug and class as printedNDCTotal acquisition costTotal estimated savingsHospitals that named it
Pembrolizumab 100 MG/4ML Solution 4.000 ML UDAntineoplastics and Adjunctive Therapies00006302604$28,553,467 (Total acquisition cost of Pembrolizumab 100 MG/4ML Solution 4.000 ML UD, page 5 of the report PDF)$10,750,171 (Total estimated savings of Pembrolizumab 100 MG/4ML Solution 4.000 ML UD, page 5 of the report PDF)9 (Hospitals that named Pembrolizumab 100 MG/4ML Solution 4.000 ML UD, page 5 of the report PDF)
Elexacaftor-Tezacaftor-Ivacaftor 100-50-75 & 150 MG Tablet Therapy Pack 84.000 EA UUAntihistamines/Nasal Agents/Cough and Cold/Respiratory/Misc - Misc51167033101$11,958,418 (Total acquisition cost of Elexacaftor-Tezacaftor-Ivacaftor 100-50-75 & 150 MG Tablet Therapy Pack 84.000 EA UU, page 5 of the report PDF)$3,759,963 (Total estimated savings of Elexacaftor-Tezacaftor-Ivacaftor 100-50-75 & 150 MG Tablet Therapy Pack 84.000 EA UU, page 5 of the report PDF)1 (Hospitals that named Elexacaftor-Tezacaftor-Ivacaftor 100-50-75 & 150 MG Tablet Therapy Pack 84.000 EA UU, page 5 of the report PDF)
Ocrelizumab 300 MG/10ML Solution 10.000 ML UDPsychotherapeutic and Neurological Agents - Miscellaneous - Misc50242015001$8,831,914 (Total acquisition cost of Ocrelizumab 300 MG/10ML Solution 10.000 ML UD, page 5 of the report PDF)$4,425,309 (Total estimated savings of Ocrelizumab 300 MG/10ML Solution 10.000 ML UD, page 5 of the report PDF)13 (Hospitals that named Ocrelizumab 300 MG/10ML Solution 10.000 ML UD, page 5 of the report PDF)
Daratumumab-Hyaluronidase-fihj 1800-30000 MG- UT/15ML Solution 15.000 ML UDAntineoplastics and Adjunctive Therapies57894050301$3,932,906 (Total acquisition cost of Daratumumab-Hyaluronidase-fihj 1800-30000 MG- UT/15ML Solution 15.000 ML UD, page 5 of the report PDF)$2,280,530 (Total estimated savings of Daratumumab-Hyaluronidase-fihj 1800-30000 MG- UT/15ML Solution 15.000 ML UD, page 5 of the report PDF)4 (Hospitals that named Daratumumab-Hyaluronidase-fihj 1800-30000 MG- UT/15ML Solution 15.000 ML UD, page 5 of the report PDF)
Vedolizumab 300 MG Solution Reconstituted 1.000 EA UDGastrointestinal Agents - Misc64764030020$2,931,924 (Total acquisition cost of Vedolizumab 300 MG Solution Reconstituted 1.000 EA UD, page 5 of the report PDF)$3,083,251 (Total estimated savings of Vedolizumab 300 MG Solution Reconstituted 1.000 EA UD, page 5 of the report PDF)5 (Hospitals that named Vedolizumab 300 MG Solution Reconstituted 1.000 EA UD, page 5 of the report PDF)
Pembrolizumab 100 MG/4ML Solution 4.000 ML UDAntineoplastics and Adjunctive Therapies00006302602$1,573,278 (Total acquisition cost of Pembrolizumab 100 MG/4ML Solution 4.000 ML UD, page 5 of the report PDF)$526,113 (Total estimated savings of Pembrolizumab 100 MG/4ML Solution 4.000 ML UD, page 5 of the report PDF)2 (Hospitals that named Pembrolizumab 100 MG/4ML Solution 4.000 ML UD, page 5 of the report PDF)
Nivolumab 240 MG/24ML Solution 24.000 ML UDAntineoplastics and Adjunctive Therapies00003373413$1,554,330 (Total acquisition cost of Nivolumab 240 MG/24ML Solution 24.000 ML UD, page 5 of the report PDF)$667,700 (Total estimated savings of Nivolumab 240 MG/24ML Solution 24.000 ML UD, page 5 of the report PDF)2 (Hospitals that named Nivolumab 240 MG/24ML Solution 24.000 ML UD, page 5 of the report PDF)
Immune Globulin (Human) IV 20 GM/200ML Solution 200.000 ML UDPassive Immunizing and Treatment Agents44206043820$775,958 (Total acquisition cost of Immune Globulin (Human) IV 20 GM/200ML Solution 200.000 ML UD, page 5 of the report PDF)$209,014 (Total estimated savings of Immune Globulin (Human) IV 20 GM/200ML Solution 200.000 ML UD, page 5 of the report PDF)5 (Hospitals that named Immune Globulin (Human) IV 20 GM/200ML Solution 200.000 ML UD, page 5 of the report PDF)
Ipilimumab 200 MG/40ML Solution 40.000 ML UDAntineoplastics and Adjunctive Therapies00003232822$666,307 (Total acquisition cost of Ipilimumab 200 MG/40ML Solution 40.000 ML UD, page 5 of the report PDF)$288,976 (Total estimated savings of Ipilimumab 200 MG/40ML Solution 40.000 ML UD, page 5 of the report PDF)2 (Hospitals that named Ipilimumab 200 MG/40ML Solution 40.000 ML UD, page 5 of the report PDF)
Elosulfase Alfa 5 MG/5ML Solution 5.000 ML UDEndocrine and Metabolic Agents - Misc68135010001$629,595 (Total acquisition cost of Elosulfase Alfa 5 MG/5ML Solution 5.000 ML UD, page 5 of the report PDF)$221,425 (Total estimated savings of Elosulfase Alfa 5 MG/5ML Solution 5.000 ML UD, page 5 of the report PDF)1 (Hospitals that named Elosulfase Alfa 5 MG/5ML Solution 5.000 ML UD, page 5 of the report PDF)
Apixaban 5 MG Tablet 60.000 EAHematological Agents - Anticoagulants00003089421$484,490 (Total acquisition cost of Apixaban 5 MG Tablet 60.000 EA, page 5 of the report PDF)$327,943 (Total estimated savings of Apixaban 5 MG Tablet 60.000 EA, page 5 of the report PDF)1 (Hospitals that named Apixaban 5 MG Tablet 60.000 EA, page 5 of the report PDF)
Aflibercept 2 MG/0.05ML Solution Prefilled Syringe 0.050 ML UDOphthalmic Agents61755000501$286,791 (Total acquisition cost of Aflibercept 2 MG/0.05ML Solution Prefilled Syringe 0.050 ML UD, page 5 of the report PDF)$138,709 (Total estimated savings of Aflibercept 2 MG/0.05ML Solution Prefilled Syringe 0.050 ML UD, page 5 of the report PDF)1 (Hospitals that named Aflibercept 2 MG/0.05ML Solution Prefilled Syringe 0.050 ML UD, page 5 of the report PDF)
Immune Globulin (Human) IV 40 GM/400ML Solution 400.000 ML UDPassive Immunizing and Treatment Agents44206043940$283,016 (Total acquisition cost of Immune Globulin (Human) IV 40 GM/400ML Solution 400.000 ML UD, page 5 of the report PDF)$77,351 (Total estimated savings of Immune Globulin (Human) IV 40 GM/400ML Solution 400.000 ML UD, page 5 of the report PDF)3 (Hospitals that named Immune Globulin (Human) IV 40 GM/400ML Solution 400.000 ML UD, page 5 of the report PDF)
Denosumab 60 MG/ML Solution Prefilled Syringe 1.000 ML UDEndocrine and Metabolic Agents - Misc55513071001$238,338 (Total acquisition cost of Denosumab 60 MG/ML Solution Prefilled Syringe 1.000 ML UD, page 5 of the report PDF)$299,569 (Total estimated savings of Denosumab 60 MG/ML Solution Prefilled Syringe 1.000 ML UD, page 5 of the report PDF)2 (Hospitals that named Denosumab 60 MG/ML Solution Prefilled Syringe 1.000 ML UD, page 5 of the report PDF)
Inebilizumab-cdon 100 MG/10ML Solution 10.000 ML UDMiscellaneous Therapeutic Classes75987015003$206,112 (Total acquisition cost of Inebilizumab-cdon 100 MG/10ML Solution 10.000 ML UD, page 5 of the report PDF)$64,996 (Total estimated savings of Inebilizumab-cdon 100 MG/10ML Solution 10.000 ML UD, page 5 of the report PDF)1 (Hospitals that named Inebilizumab-cdon 100 MG/10ML Solution 10.000 ML UD, page 5 of the report PDF)
Omalizumab 150 MG/ML Solution Prefilled Syringe 1.000 ML UDAntihistamines/Nasal Agents/Cough and Cold/Respiratory/Misc - Antiasthmatic and Bronchodilator Agents50242021501$195,514 (Total acquisition cost of Omalizumab 150 MG/ML Solution Prefilled Syringe 1.000 ML UD, page 6 of the report PDF)$133,201 (Total estimated savings of Omalizumab 150 MG/ML Solution Prefilled Syringe 1.000 ML UD, page 6 of the report PDF)3 (Hospitals that named Omalizumab 150 MG/ML Solution Prefilled Syringe 1.000 ML UD, page 6 of the report PDF)
Somatropin 15 MG/1.5ML Solution Pen-injector 1.500 ML UUEndocrine and Metabolic Agents - Misc00169770821$172,662 (Total acquisition cost of Somatropin 15 MG/1.5ML Solution Pen-injector 1.500 ML UU, page 6 of the report PDF)$12,487 (Total estimated savings of Somatropin 15 MG/1.5ML Solution Pen-injector 1.500 ML UU, page 6 of the report PDF)1 (Hospitals that named Somatropin 15 MG/1.5ML Solution Pen-injector 1.500 ML UU, page 6 of the report PDF)
Faricimab-svoa 6 MG/0.05ML Solution 0.050 ML UDOphthalmic Agents50242009601$123,307 (Total acquisition cost of Faricimab-svoa 6 MG/0.05ML Solution 0.050 ML UD, page 6 of the report PDF)$50,754 (Total estimated savings of Faricimab-svoa 6 MG/0.05ML Solution 0.050 ML UD, page 6 of the report PDF)1 (Hospitals that named Faricimab-svoa 6 MG/0.05ML Solution 0.050 ML UD, page 6 of the report PDF)
Semaglutide 2 MG/3ML Solution Pen-injector 3.000 ML UUEndocrine and Metabolic Agents - Antidiabetics00169418113$107,969 (Total acquisition cost of Semaglutide 2 MG/3ML Solution Pen-injector 3.000 ML UU, page 6 of the report PDF)$51,424 (Total estimated savings of Semaglutide 2 MG/3ML Solution Pen-injector 3.000 ML UU, page 6 of the report PDF)1 (Hospitals that named Semaglutide 2 MG/3ML Solution Pen-injector 3.000 ML UU, page 6 of the report PDF)
Semaglutide 4 MG/3ML Solution Pen-injector 3.000 ML UUEndocrine and Metabolic Agents - Antidiabetics00169413013$96,431 (Total acquisition cost of Semaglutide 4 MG/3ML Solution Pen-injector 3.000 ML UU, page 6 of the report PDF)$42,145 (Total estimated savings of Semaglutide 4 MG/3ML Solution Pen-injector 3.000 ML UU, page 6 of the report PDF)1 (Hospitals that named Semaglutide 4 MG/3ML Solution Pen-injector 3.000 ML UU, page 6 of the report PDF)
Ublituximab-xiiy 150 MG/6ML Solution 6.000 ML UDPsychotherapeutic and Neurological Agents - Miscellaneous - Misc73150015006$81,289 (Total acquisition cost of Ublituximab-xiiy 150 MG/6ML Solution 6.000 ML UD, page 6 of the report PDF)$39,792 (Total estimated savings of Ublituximab-xiiy 150 MG/6ML Solution 6.000 ML UD, page 6 of the report PDF)1 (Hospitals that named Ublituximab-xiiy 150 MG/6ML Solution 6.000 ML UD, page 6 of the report PDF)
Risankizumab-rzaa (Crohn's) 600 MG/10ML Solution 10.000 ML UDGastrointestinal Agents - Misc00074501501$62,516 (Total acquisition cost of Risankizumab-rzaa (Crohn's) 600 MG/10ML Solution 10.000 ML UD, page 6 of the report PDF)$61,509 (Total estimated savings of Risankizumab-rzaa (Crohn's) 600 MG/10ML Solution 10.000 ML UD, page 6 of the report PDF)1 (Hospitals that named Risankizumab-rzaa (Crohn's) 600 MG/10ML Solution 10.000 ML UD, page 6 of the report PDF)
Remdesivir 100 MG Solution Reconstituted 1.000 EA UDAnti-Infective Agents - Antivirals61958290102$59,249 (Total acquisition cost of Remdesivir 100 MG Solution Reconstituted 1.000 EA UD, page 6 of the report PDF)$22,876 (Total estimated savings of Remdesivir 100 MG Solution Reconstituted 1.000 EA UD, page 6 of the report PDF)1 (Hospitals that named Remdesivir 100 MG Solution Reconstituted 1.000 EA UD, page 6 of the report PDF)
Tremelimumab-actl 300 MG/15ML Solution 15.000 ML UDAntineoplastics and Adjunctive Therapies00310453530$58,883 (Total acquisition cost of Tremelimumab-actl 300 MG/15ML Solution 15.000 ML UD, page 6 of the report PDF)$21,975 (Total estimated savings of Tremelimumab-actl 300 MG/15ML Solution 15.000 ML UD, page 6 of the report PDF)2 (Hospitals that named Tremelimumab-actl 300 MG/15ML Solution 15.000 ML UD, page 6 of the report PDF)
Cladribine (Multiple Sclerosis) 10 MG Tablet Therapy Pack 10.000 EA UUPsychotherapeutic and Neurological Agents - Miscellaneous - Misc44087400000$56,054 (Total acquisition cost of Cladribine (Multiple Sclerosis) 10 MG Tablet Therapy Pack 10.000 EA UU, page 6 of the report PDF)$48,003 (Total estimated savings of Cladribine (Multiple Sclerosis) 10 MG Tablet Therapy Pack 10.000 EA UU, page 6 of the report PDF)1 (Hospitals that named Cladribine (Multiple Sclerosis) 10 MG Tablet Therapy Pack 10.000 EA UU, page 6 of the report PDF)
Glecaprevir-Pibrentasvir 100-40 MG Tablet 84.000 EA UUAnti-Infective Agents - Antivirals00074262528$35,785 (Total acquisition cost of Glecaprevir-Pibrentasvir 100-40 MG Tablet 84.000 EA UU, page 6 of the report PDF)$15,694 (Total estimated savings of Glecaprevir-Pibrentasvir 100-40 MG Tablet 84.000 EA UU, page 6 of the report PDF)2 (Hospitals that named Glecaprevir-Pibrentasvir 100-40 MG Tablet 84.000 EA UU, page 6 of the report PDF)
Tenecteplase 50 MG Kit 1.000 EA UUHematological Agents - Misc50242012047$30,478 (Total acquisition cost of Tenecteplase 50 MG Kit 1.000 EA UU, page 6 of the report PDF)$93,878 (Total estimated savings of Tenecteplase 50 MG Kit 1.000 EA UU, page 6 of the report PDF)2 (Hospitals that named Tenecteplase 50 MG Kit 1.000 EA UU, page 6 of the report PDF)
Semaglutide 8 MG/3ML Solution Pen-injector 3.000 ML UUEndocrine and Metabolic Agents - Antidiabetics00169477212$29,405 (Total acquisition cost of Semaglutide 8 MG/3ML Solution Pen-injector 3.000 ML UU, page 6 of the report PDF)$20,213 (Total estimated savings of Semaglutide 8 MG/3ML Solution Pen-injector 3.000 ML UU, page 6 of the report PDF)1 (Hospitals that named Semaglutide 8 MG/3ML Solution Pen-injector 3.000 ML UU, page 6 of the report PDF)
Olaparib 150 MG Tablet 120.000 EAAntineoplastics and Adjunctive Therapies00310067912$24,346 (Total acquisition cost of Olaparib 150 MG Tablet 120.000 EA, page 6 of the report PDF)$10,249 (Total estimated savings of Olaparib 150 MG Tablet 120.000 EA, page 6 of the report PDF)2 (Hospitals that named Olaparib 150 MG Tablet 120.000 EA, page 6 of the report PDF)
Prothrombin Complex Concentrate Human 500 UNIT Kit 1.000 EA UUHematological Agents - Misc63833038602$19,281 (Total acquisition cost of Prothrombin Complex Concentrate Human 500 UNIT Kit 1.000 EA UU, page 6 of the report PDF)$9,744 (Total estimated savings of Prothrombin Complex Concentrate Human 500 UNIT Kit 1.000 EA UU, page 6 of the report PDF)1 (Hospitals that named Prothrombin Complex Concentrate Human 500 UNIT Kit 1.000 EA UU, page 6 of the report PDF)
Alteplase 100 MG Solution Reconstituted 1.000 EA UDHematological Agents - Misc50242008527$16,176 (Total acquisition cost of Alteplase 100 MG Solution Reconstituted 1.000 EA UD, page 6 of the report PDF)$1,174 (Total estimated savings of Alteplase 100 MG Solution Reconstituted 1.000 EA UD, page 6 of the report PDF)2 (Hospitals that named Alteplase 100 MG Solution Reconstituted 1.000 EA UD, page 6 of the report PDF)
Pirtobrutinib 100 MG Tablet 60.000 EAAntineoplastics and Adjunctive Therapies00002702660$16,090 (Total acquisition cost of Pirtobrutinib 100 MG Tablet 60.000 EA, page 6 of the report PDF)$6,868 (Total estimated savings of Pirtobrutinib 100 MG Tablet 60.000 EA, page 6 of the report PDF)1 (Hospitals that named Pirtobrutinib 100 MG Tablet 60.000 EA, page 6 of the report PDF)
Belimumab 400 MG Solution Reconstituted 1.000 EA UDMiscellaneous Therapeutic Classes49401010201$15,420 (Total acquisition cost of Belimumab 400 MG Solution Reconstituted 1.000 EA UD, page 6 of the report PDF)$5,660 (Total estimated savings of Belimumab 400 MG Solution Reconstituted 1.000 EA UD, page 6 of the report PDF)1 (Hospitals that named Belimumab 400 MG Solution Reconstituted 1.000 EA UD, page 6 of the report PDF)
Lenvatinib Mesylate 2 x 10 MG Capsule Therapy Pack 60.000 EA UUAntineoplastics and Adjunctive Therapies62856072030$12,779 (Total acquisition cost of Lenvatinib Mesylate 2 x 10 MG Capsule Therapy Pack 60.000 EA UU, page 6 of the report PDF)$12,113 (Total estimated savings of Lenvatinib Mesylate 2 x 10 MG Capsule Therapy Pack 60.000 EA UU, page 6 of the report PDF)1 (Hospitals that named Lenvatinib Mesylate 2 x 10 MG Capsule Therapy Pack 60.000 EA UU, page 6 of the report PDF)
Zanubrutinib 80 MG Capsule 120.000 EAAntineoplastics and Adjunctive Therapies72579001102$11,080 (Total acquisition cost of Zanubrutinib 80 MG Capsule 120.000 EA, page 6 of the report PDF)$32,246 (Total estimated savings of Zanubrutinib 80 MG Capsule 120.000 EA, page 6 of the report PDF)1 (Hospitals that named Zanubrutinib 80 MG Capsule 120.000 EA, page 6 of the report PDF)
Risankizumab-rzaa 150 MG/ML Solution Auto-injector 1.000 ML UDDermatologicals00074210001$10,170 (Total acquisition cost of Risankizumab-rzaa 150 MG/ML Solution Auto-injector 1.000 ML UD, page 6 of the report PDF)$10,771 (Total estimated savings of Risankizumab-rzaa 150 MG/ML Solution Auto-injector 1.000 ML UD, page 6 of the report PDF)1 (Hospitals that named Risankizumab-rzaa 150 MG/ML Solution Auto-injector 1.000 ML UD, page 6 of the report PDF)
Imetelstat Sodium 188 MG Solution Reconstituted 1.000 EA UDAntineoplastics and Adjunctive Therapies82959011101$7,788 (Total acquisition cost of Imetelstat Sodium 188 MG Solution Reconstituted 1.000 EA UD, page 6 of the report PDF)$14,131 (Total estimated savings of Imetelstat Sodium 188 MG Solution Reconstituted 1.000 EA UD, page 6 of the report PDF)1 (Hospitals that named Imetelstat Sodium 188 MG Solution Reconstituted 1.000 EA UD, page 6 of the report PDF)

Drug names, classes and NDCs are the report's own words. Select a column heading to sort. Back to top

Most frequently dispensed drugs

The report's title for this table is "Top 3 Most Frequently Dispensed 340B Prescription Drugs". It lists 54 drugs on pages 7 to 9 of the report. The report says this table is limited to drugs the hospitals dispensed, and may leave out drugs they administered (page 7 (Page 7 of the report PDF)).

The total amount spent across each of the 27 hospitals’ top 3 most frequently dispensed prescription drugs purchased under the 340B Drug Program represented 2.4% of the total 340B drug acquisition cost.

The sentence the report prints above the table, word for word. Open the page (Page 7 of the report PDF)
Values Reported for Top 3 Most Frequently Dispensed Drugs Acquired under the Hospitals' 340B Drug Program: 54 drugs as printed
Drug and class as printedNDCTotal acquisition costTotal estimated savingsHospitals that named it
Pembrolizumab 100 MG/4ML Solution 4.000 ML UDAntineoplastics and Adjunctive Therapies00006302602$4,156,458 (Total acquisition cost of Pembrolizumab 100 MG/4ML Solution 4.000 ML UD, page 7 of the report PDF)$1,737,661 (Total estimated savings of Pembrolizumab 100 MG/4ML Solution 4.000 ML UD, page 7 of the report PDF)1 (Hospitals that named Pembrolizumab 100 MG/4ML Solution 4.000 ML UD, page 7 of the report PDF)
OnabotulinumtoxinA 100 UNIT Solution Reconstituted 1.000 EA UDNeuromuscular Agents - Neuromuscular Agents00023114501$2,194,370 (Total acquisition cost of OnabotulinumtoxinA 100 UNIT Solution Reconstituted 1.000 EA UD, page 7 of the report PDF)$900,606 (Total estimated savings of OnabotulinumtoxinA 100 UNIT Solution Reconstituted 1.000 EA UD, page 7 of the report PDF)2 (Hospitals that named OnabotulinumtoxinA 100 UNIT Solution Reconstituted 1.000 EA UD, page 7 of the report PDF)
Infliximab-abda 100 MG Solution Reconstituted 1.000 EA UDGastrointestinal Agents - Misc78206016201$777,210 (Total acquisition cost of Infliximab-abda 100 MG Solution Reconstituted 1.000 EA UD, page 7 of the report PDF)$573,252 (Total estimated savings of Infliximab-abda 100 MG Solution Reconstituted 1.000 EA UD, page 7 of the report PDF)3 (Hospitals that named Infliximab-abda 100 MG Solution Reconstituted 1.000 EA UD, page 7 of the report PDF)
Elosulfase Alfa 5 MG/5ML Solution 5.000 ML UDEndocrine and Metabolic Agents - Misc68135010001$629,595 (Total acquisition cost of Elosulfase Alfa 5 MG/5ML Solution 5.000 ML UD, page 7 of the report PDF)$221,425 (Total estimated savings of Elosulfase Alfa 5 MG/5ML Solution 5.000 ML UD, page 7 of the report PDF)1 (Hospitals that named Elosulfase Alfa 5 MG/5ML Solution 5.000 ML UD, page 7 of the report PDF)
Infliximab 100 MG Solution Reconstituted 1.000 EA UDGastrointestinal Agents - Misc57894003001$578,646 (Total acquisition cost of Infliximab 100 MG Solution Reconstituted 1.000 EA UD, page 7 of the report PDF)$2,081,635 (Total estimated savings of Infliximab 100 MG Solution Reconstituted 1.000 EA UD, page 7 of the report PDF)4 (Hospitals that named Infliximab 100 MG Solution Reconstituted 1.000 EA UD, page 7 of the report PDF)
Apixaban 5 MG Tablet 60.000 EAHematological Agents - Anticoagulants00003089421$524,336 (Total acquisition cost of Apixaban 5 MG Tablet 60.000 EA, page 7 of the report PDF)$1,240,088 (Total estimated savings of Apixaban 5 MG Tablet 60.000 EA, page 7 of the report PDF)6 (Hospitals that named Apixaban 5 MG Tablet 60.000 EA, page 7 of the report PDF)
Infliximab 100 MG Solution Reconstituted 1.000 EA UDGastrointestinal Agents - Misc57894016001$452,722 (Total acquisition cost of Infliximab 100 MG Solution Reconstituted 1.000 EA UD, page 7 of the report PDF)$233,583 (Total estimated savings of Infliximab 100 MG Solution Reconstituted 1.000 EA UD, page 7 of the report PDF)4 (Hospitals that named Infliximab 100 MG Solution Reconstituted 1.000 EA UD, page 7 of the report PDF)
Semaglutide 2 MG/3ML Solution Pen-injector 3.000 ML UUEndocrine and Metabolic Agents - Antidiabetics00169418113$107,969 (Total acquisition cost of Semaglutide 2 MG/3ML Solution Pen-injector 3.000 ML UU, page 7 of the report PDF)$51,424 (Total estimated savings of Semaglutide 2 MG/3ML Solution Pen-injector 3.000 ML UU, page 7 of the report PDF)1 (Hospitals that named Semaglutide 2 MG/3ML Solution Pen-injector 3.000 ML UU, page 7 of the report PDF)
Semaglutide 4 MG/3ML Solution Pen-injector 3.000 ML UUEndocrine and Metabolic Agents - Antidiabetics00169413013$96,431 (Total acquisition cost of Semaglutide 4 MG/3ML Solution Pen-injector 3.000 ML UU, page 7 of the report PDF)$42,145 (Total estimated savings of Semaglutide 4 MG/3ML Solution Pen-injector 3.000 ML UU, page 7 of the report PDF)1 (Hospitals that named Semaglutide 4 MG/3ML Solution Pen-injector 3.000 ML UU, page 7 of the report PDF)
Ferumoxytol 510 MG/17ML Solution 17.000 ML UDHematological Agents - Hematopoietic Agents00781315401$87,851 (Total acquisition cost of Ferumoxytol 510 MG/17ML Solution 17.000 ML UD, page 7 of the report PDF)$8,285 (Total estimated savings of Ferumoxytol 510 MG/17ML Solution 17.000 ML UD, page 7 of the report PDF)1 (Hospitals that named Ferumoxytol 510 MG/17ML Solution 17.000 ML UD, page 7 of the report PDF)
Denosumab 60 MG/ML Solution Prefilled Syringe 1.000 ML UDEndocrine and Metabolic Agents - Misc55513071001$59,621 (Total acquisition cost of Denosumab 60 MG/ML Solution Prefilled Syringe 1.000 ML UD, page 7 of the report PDF)$170,690 (Total estimated savings of Denosumab 60 MG/ML Solution Prefilled Syringe 1.000 ML UD, page 7 of the report PDF)1 (Hospitals that named Denosumab 60 MG/ML Solution Prefilled Syringe 1.000 ML UD, page 7 of the report PDF)
Remdesivir 100 MG Solution Reconstituted 1.000 EA UDAnti-Infective Agents - Antivirals61958290102$59,249 (Total acquisition cost of Remdesivir 100 MG Solution Reconstituted 1.000 EA UD, page 7 of the report PDF)$37,329 (Total estimated savings of Remdesivir 100 MG Solution Reconstituted 1.000 EA UD, page 7 of the report PDF)1 (Hospitals that named Remdesivir 100 MG Solution Reconstituted 1.000 EA UD, page 7 of the report PDF)
Ferric Carboxymaltose 750 MG/15ML Solution 15.000 ML UDHematological Agents - Hematopoietic Agents00517065001$47,308 (Total acquisition cost of Ferric Carboxymaltose 750 MG/15ML Solution 15.000 ML UD, page 7 of the report PDF)$28,201 (Total estimated savings of Ferric Carboxymaltose 750 MG/15ML Solution 15.000 ML UD, page 7 of the report PDF)1 (Hospitals that named Ferric Carboxymaltose 750 MG/15ML Solution 15.000 ML UD, page 7 of the report PDF)
Propofol 200 MG/20ML Emulsion 20.000 ML UDGeneral Anesthetics25021060820$29,311 (Total acquisition cost of Propofol 200 MG/20ML Emulsion 20.000 ML UD, page 8 of the report PDF)$11,006 (Total estimated savings of Propofol 200 MG/20ML Emulsion 20.000 ML UD, page 8 of the report PDF)1 (Hospitals that named Propofol 200 MG/20ML Emulsion 20.000 ML UD, page 8 of the report PDF)
Albuterol Sulfate 108 (90 Base) MCG/ACT Aerosol Solution 18.000 GM UUAntihistamines/Nasal Agents/Cough and Cold/Respiratory/Misc - Antiasthmatic and Bronchodilator Agents66993001968$19,264 (Total acquisition cost of Albuterol Sulfate 108 (90 Base) MCG/ACT Aerosol Solution 18.000 GM UU, page 8 of the report PDF)$20,517 (Total estimated savings of Albuterol Sulfate 108 (90 Base) MCG/ACT Aerosol Solution 18.000 GM UU, page 8 of the report PDF)3 (Hospitals that named Albuterol Sulfate 108 (90 Base) MCG/ACT Aerosol Solution 18.000 GM UU, page 8 of the report PDF)
Iohexol 300 MG/ML Solution 100.000 ML UDDiagnostic Products00407141363$17,022 (Total acquisition cost of Iohexol 300 MG/ML Solution 100.000 ML UD, page 8 of the report PDF)$42,685 (Total estimated savings of Iohexol 300 MG/ML Solution 100.000 ML UD, page 8 of the report PDF)1 (Hospitals that named Iohexol 300 MG/ML Solution 100.000 ML UD, page 8 of the report PDF)
Lactated Ringer's Solution 1000.000 ML UDNutritional Products - Minerals & Electrolytes00264775000$14,323 (Total acquisition cost of Lactated Ringer's Solution 1000.000 ML UD, page 8 of the report PDF)$12,207 (Total estimated savings of Lactated Ringer's Solution 1000.000 ML UD, page 8 of the report PDF)1 (Hospitals that named Lactated Ringer's Solution 1000.000 ML UD, page 8 of the report PDF)
Albuterol Sulfate 108 (90 Base) MCG/ACT Aerosol Solution 8.500 GM UUAntihistamines/Nasal Agents/Cough and Cold/Respiratory/Misc - Antiasthmatic and Bronchodilator Agents68180096301$11,894 (Total acquisition cost of Albuterol Sulfate 108 (90 Base) MCG/ACT Aerosol Solution 8.500 GM UU, page 8 of the report PDF)$19,725 (Total estimated savings of Albuterol Sulfate 108 (90 Base) MCG/ACT Aerosol Solution 8.500 GM UU, page 8 of the report PDF)5 (Hospitals that named Albuterol Sulfate 108 (90 Base) MCG/ACT Aerosol Solution 8.500 GM UU, page 8 of the report PDF)
Amphotericin B Liposome 50 MG Suspension Reconstituted 1.000 EA UDAnti-Infective Agents - Antifungals62756023301$8,525 (Total acquisition cost of Amphotericin B Liposome 50 MG Suspension Reconstituted 1.000 EA UD, page 8 of the report PDF)$24,242 (Total estimated savings of Amphotericin B Liposome 50 MG Suspension Reconstituted 1.000 EA UD, page 8 of the report PDF)1 (Hospitals that named Amphotericin B Liposome 50 MG Suspension Reconstituted 1.000 EA UD, page 8 of the report PDF)
Pantoprazole Sodium 40 MG Tablet Delayed Release 90.000 EAGastrointestinal Agents - Ulcer Drugs/Antispasmodics/Anticholinergics65862056090$7,169 (Total acquisition cost of Pantoprazole Sodium 40 MG Tablet Delayed Release 90.000 EA, page 8 of the report PDF)$160,459 (Total estimated savings of Pantoprazole Sodium 40 MG Tablet Delayed Release 90.000 EA, page 8 of the report PDF)1 (Hospitals that named Pantoprazole Sodium 40 MG Tablet Delayed Release 90.000 EA, page 8 of the report PDF)
Oxycodone HCl 5 MG Tablet 100.000 EAAnalgesics - Opioid00406055201$6,069 (Total acquisition cost of Oxycodone HCl 5 MG Tablet 100.000 EA, page 8 of the report PDF)$15,533 (Total estimated savings of Oxycodone HCl 5 MG Tablet 100.000 EA, page 8 of the report PDF)1 (Hospitals that named Oxycodone HCl 5 MG Tablet 100.000 EA, page 8 of the report PDF)
Palonosetron HCl 0.25 MG/5ML Solution 5.000 ML UDGastrointestinal Agents - Antiemetics60505619301$5,706 (Total acquisition cost of Palonosetron HCl 0.25 MG/5ML Solution 5.000 ML UD, page 8 of the report PDF)$73,515 (Total estimated savings of Palonosetron HCl 0.25 MG/5ML Solution 5.000 ML UD, page 8 of the report PDF)2 (Hospitals that named Palonosetron HCl 0.25 MG/5ML Solution 5.000 ML UD, page 8 of the report PDF)
Sodium Chloride 0.9 % Solution 1000.000 ML UDNutritional Products - Minerals and Electrolytes00990798309$5,505 (Total acquisition cost of Sodium Chloride 0.9 % Solution 1000.000 ML UD, page 8 of the report PDF)$1,812 (Total estimated savings of Sodium Chloride 0.9 % Solution 1000.000 ML UD, page 8 of the report PDF)1 (Hospitals that named Sodium Chloride 0.9 % Solution 1000.000 ML UD, page 8 of the report PDF)
Propofol 200 MG/20ML Emulsion 20.000 ML UDGeneral Anesthetics63323026929$5,448 (Total acquisition cost of Propofol 200 MG/20ML Emulsion 20.000 ML UD, page 8 of the report PDF)$25,027 (Total estimated savings of Propofol 200 MG/20ML Emulsion 20.000 ML UD, page 8 of the report PDF)2 (Hospitals that named Propofol 200 MG/20ML Emulsion 20.000 ML UD, page 8 of the report PDF)
Apixaban 2.5 MG Tablet 60.000 EAHematological Agents - Anticoagulants00003089321$5,428 (Total acquisition cost of Apixaban 2.5 MG Tablet 60.000 EA, page 8 of the report PDF)$108,904 (Total estimated savings of Apixaban 2.5 MG Tablet 60.000 EA, page 8 of the report PDF)3 (Hospitals that named Apixaban 2.5 MG Tablet 60.000 EA, page 8 of the report PDF)
Triamcinolone Acetonide 40 MG/ML Suspension 1.000 ML UDEndocrine and Metabolic Agents - Corticosteroids00703024101$3,548 (Total acquisition cost of Triamcinolone Acetonide 40 MG/ML Suspension 1.000 ML UD, page 8 of the report PDF)$132 (Total estimated savings of Triamcinolone Acetonide 40 MG/ML Suspension 1.000 ML UD, page 8 of the report PDF)2 (Hospitals that named Triamcinolone Acetonide 40 MG/ML Suspension 1.000 ML UD, page 8 of the report PDF)
Omeprazole 20 MG Capsule Delayed Release 100.000 EAGastrointestinal Agents - Ulcer Drugs/Antispasmodics/Anticholinergics55111015801$3,525 (Total acquisition cost of Omeprazole 20 MG Capsule Delayed Release 100.000 EA, page 8 of the report PDF)$131,515 (Total estimated savings of Omeprazole 20 MG Capsule Delayed Release 100.000 EA, page 8 of the report PDF)1 (Hospitals that named Omeprazole 20 MG Capsule Delayed Release 100.000 EA, page 8 of the report PDF)
Methylprednisolone Acetate 40 MG/ML Suspension 1.000 ML UDEndocrine and Metabolic Agents - Corticosteroids70121157301$2,621 (Total acquisition cost of Methylprednisolone Acetate 40 MG/ML Suspension 1.000 ML UD, page 8 of the report PDF)$2,931 (Total estimated savings of Methylprednisolone Acetate 40 MG/ML Suspension 1.000 ML UD, page 8 of the report PDF)1 (Hospitals that named Methylprednisolone Acetate 40 MG/ML Suspension 1.000 ML UD, page 8 of the report PDF)
Pantoprazole Sodium 40 MG Tablet Delayed Release 1000.000 EAGastrointestinal Agents - Ulcer Drugs/Antispasmodics/Anticholinergics65862056099$1,943 (Total acquisition cost of Pantoprazole Sodium 40 MG Tablet Delayed Release 1000.000 EA, page 8 of the report PDF)$746 (Total estimated savings of Pantoprazole Sodium 40 MG Tablet Delayed Release 1000.000 EA, page 8 of the report PDF)1 (Hospitals that named Pantoprazole Sodium 40 MG Tablet Delayed Release 1000.000 EA, page 8 of the report PDF)
Triamcinolone Acetonide 40 MG/ML Suspension 1.000 ML UDEndocrine and Metabolic Agents - Corticosteroids00003029305$1,832 (Total acquisition cost of Triamcinolone Acetonide 40 MG/ML Suspension 1.000 ML UD, page 8 of the report PDF)$2,657 (Total estimated savings of Triamcinolone Acetonide 40 MG/ML Suspension 1.000 ML UD, page 8 of the report PDF)1 (Hospitals that named Triamcinolone Acetonide 40 MG/ML Suspension 1.000 ML UD, page 8 of the report PDF)
Acetaminophen 325 MG Tablet 100.000 EA UDAnalgesics - Nonnarcotic00904677361$1,531 (Total acquisition cost of Acetaminophen 325 MG Tablet 100.000 EA UD, page 8 of the report PDF)$1,621 (Total estimated savings of Acetaminophen 325 MG Tablet 100.000 EA UD, page 8 of the report PDF)1 (Hospitals that named Acetaminophen 325 MG Tablet 100.000 EA UD, page 8 of the report PDF)
Atorvastatin Calcium 20 MG Tablet 1000.000 EACardiovascular Agents - Antihyperlipidemics70377007813$1,089 (Total acquisition cost of Atorvastatin Calcium 20 MG Tablet 1000.000 EA, page 8 of the report PDF)$8,913 (Total estimated savings of Atorvastatin Calcium 20 MG Tablet 1000.000 EA, page 8 of the report PDF)1 (Hospitals that named Atorvastatin Calcium 20 MG Tablet 1000.000 EA, page 8 of the report PDF)
Amoxicillin & Pot Clavulanate 875-125 MG Tablet 20.000 EAAnti-Infective Agents - Penicillins65862050320$983 (Total acquisition cost of Amoxicillin & Pot Clavulanate 875-125 MG Tablet 20.000 EA, page 8 of the report PDF)$2,555 (Total estimated savings of Amoxicillin & Pot Clavulanate 875-125 MG Tablet 20.000 EA, page 8 of the report PDF)1 (Hospitals that named Amoxicillin & Pot Clavulanate 875-125 MG Tablet 20.000 EA, page 8 of the report PDF)
Gabapentin 300 MG Capsule 1000.000 EANeuromuscular Agents - Anticonvulsants50228018010$945 (Total acquisition cost of Gabapentin 300 MG Capsule 1000.000 EA, page 8 of the report PDF)$4,927 (Total estimated savings of Gabapentin 300 MG Capsule 1000.000 EA, page 8 of the report PDF)1 (Hospitals that named Gabapentin 300 MG Capsule 1000.000 EA, page 8 of the report PDF)
Pantoprazole Sodium 40 MG Tablet Delayed Release 1000.000 EAGastrointestinal Agents - Ulcer Drugs/Antispasmodics/Anticholinergics00378668910$732 (Total acquisition cost of Pantoprazole Sodium 40 MG Tablet Delayed Release 1000.000 EA, page 8 of the report PDF)$5,857 (Total estimated savings of Pantoprazole Sodium 40 MG Tablet Delayed Release 1000.000 EA, page 8 of the report PDF)1 (Hospitals that named Pantoprazole Sodium 40 MG Tablet Delayed Release 1000.000 EA, page 8 of the report PDF)
Pancrelipase (Lipase-Protease-Amylase) 36000- 114000 UNIT Capsule Delayed Release Particles 100.000 EA UUGastrointestinal Agents - Digestive Aids00032301613$725 (Total acquisition cost of Pancrelipase (Lipase-Protease-Amylase) 36000- 114000 UNIT Capsule Delayed Release Particles 100.000 EA UU, page 9 of the report PDF)$933,096 (Total estimated savings of Pancrelipase (Lipase-Protease-Amylase) 36000- 114000 UNIT Capsule Delayed Release Particles 100.000 EA UU, page 9 of the report PDF)1 (Hospitals that named Pancrelipase (Lipase-Protease-Amylase) 36000- 114000 UNIT Capsule Delayed Release Particles 100.000 EA UU, page 9 of the report PDF)
Metformin HCl 500 MG Tablet Extended Release 24 Hour 500.000 EAEndocrine and Metabolic Agents - Antidiabetics67877015905$594 (Total acquisition cost of Metformin HCl 500 MG Tablet Extended Release 24 Hour 500.000 EA, page 9 of the report PDF)$620 (Total estimated savings of Metformin HCl 500 MG Tablet Extended Release 24 Hour 500.000 EA, page 9 of the report PDF)1 (Hospitals that named Metformin HCl 500 MG Tablet Extended Release 24 Hour 500.000 EA, page 9 of the report PDF)
Metformin HCl 1000 MG Tablet 100.000 EAEndocrine and Metabolic Agents - Antidiabetics65862001001$569 (Total acquisition cost of Metformin HCl 1000 MG Tablet 100.000 EA, page 9 of the report PDF)$850 (Total estimated savings of Metformin HCl 1000 MG Tablet 100.000 EA, page 9 of the report PDF)2 (Hospitals that named Metformin HCl 1000 MG Tablet 100.000 EA, page 9 of the report PDF)
Proparacaine HCl 0.5 % Solution 15.000 ML UUOphthalmic Agents61314001601$469 (Total acquisition cost of Proparacaine HCl 0.5 % Solution 15.000 ML UU, page 9 of the report PDF)$1,153 (Total estimated savings of Proparacaine HCl 0.5 % Solution 15.000 ML UU, page 9 of the report PDF)1 (Hospitals that named Proparacaine HCl 0.5 % Solution 15.000 ML UU, page 9 of the report PDF)
Albuterol Sulfate 108 (90 Base) MCG/ACT Aerosol Solution 8.000 GM UUAntihistamines/Nasal Agents/Cough and Cold/Respiratory/Misc - Antiasthmatic and Bronchodilator Agents00173068224$373 (Total acquisition cost of Albuterol Sulfate 108 (90 Base) MCG/ACT Aerosol Solution 8.000 GM UU, page 9 of the report PDF)$997 (Total estimated savings of Albuterol Sulfate 108 (90 Base) MCG/ACT Aerosol Solution 8.000 GM UU, page 9 of the report PDF)1 (Hospitals that named Albuterol Sulfate 108 (90 Base) MCG/ACT Aerosol Solution 8.000 GM UU, page 9 of the report PDF)
Bacitracin (Topical) 500 UNIT/GM Ointment 30.000 GM UUDermatologicals00536125628$360 (Total acquisition cost of Bacitracin (Topical) 500 UNIT/GM Ointment 30.000 GM UU, page 9 of the report PDF)$170 (Total estimated savings of Bacitracin (Topical) 500 UNIT/GM Ointment 30.000 GM UU, page 9 of the report PDF)1 (Hospitals that named Bacitracin (Topical) 500 UNIT/GM Ointment 30.000 GM UU, page 9 of the report PDF)
Metformin HCl 500 MG Tablet Extended Release 24 Hour 500.000 EAEndocrine and Metabolic Agents - Antidiabetics70010049105$330 (Total acquisition cost of Metformin HCl 500 MG Tablet Extended Release 24 Hour 500.000 EA, page 9 of the report PDF)$718 (Total estimated savings of Metformin HCl 500 MG Tablet Extended Release 24 Hour 500.000 EA, page 9 of the report PDF)1 (Hospitals that named Metformin HCl 500 MG Tablet Extended Release 24 Hour 500.000 EA, page 9 of the report PDF)
Methylprednisolone Acetate 40 MG/ML Suspension 1.000 ML UDEndocrine and Metabolic Agents - Corticosteroids00009307301$329 (Total acquisition cost of Methylprednisolone Acetate 40 MG/ML Suspension 1.000 ML UD, page 9 of the report PDF)$103 (Total estimated savings of Methylprednisolone Acetate 40 MG/ML Suspension 1.000 ML UD, page 9 of the report PDF)1 (Hospitals that named Methylprednisolone Acetate 40 MG/ML Suspension 1.000 ML UD, page 9 of the report PDF)
Metformin HCl 500 MG Tablet 100.000 EAEndocrine and Metabolic Agents - Antidiabetics65862000801$271 (Total acquisition cost of Metformin HCl 500 MG Tablet 100.000 EA, page 9 of the report PDF)$329 (Total estimated savings of Metformin HCl 500 MG Tablet 100.000 EA, page 9 of the report PDF)1 (Hospitals that named Metformin HCl 500 MG Tablet 100.000 EA, page 9 of the report PDF)
Gabapentin 100 MG Capsule 500.000 EANeuromuscular Agents - Anticonvulsants67877022205$217 (Total acquisition cost of Gabapentin 100 MG Capsule 500.000 EA, page 9 of the report PDF)$318 (Total estimated savings of Gabapentin 100 MG Capsule 500.000 EA, page 9 of the report PDF)1 (Hospitals that named Gabapentin 100 MG Capsule 500.000 EA, page 9 of the report PDF)
Atorvastatin Calcium 40 MG Tablet 90.000 EACardiovascular Agents - Antihyperlipidemics72205002490$162 (Total acquisition cost of Atorvastatin Calcium 40 MG Tablet 90.000 EA, page 9 of the report PDF)$648 (Total estimated savings of Atorvastatin Calcium 40 MG Tablet 90.000 EA, page 9 of the report PDF)2 (Hospitals that named Atorvastatin Calcium 40 MG Tablet 90.000 EA, page 9 of the report PDF)
Omeprazole 40 MG Capsule Delayed Release 1000.000 EAGastrointestinal Agents - Ulcer Drugs/Antispasmodics/Anticholinergics68462039710$150 (Total acquisition cost of Omeprazole 40 MG Capsule Delayed Release 1000.000 EA, page 9 of the report PDF)$7,112 (Total estimated savings of Omeprazole 40 MG Capsule Delayed Release 1000.000 EA, page 9 of the report PDF)1 (Hospitals that named Omeprazole 40 MG Capsule Delayed Release 1000.000 EA, page 9 of the report PDF)
Atorvastatin Calcium 80 MG Tablet 90.000 EACardiovascular Agents - Antihyperlipidemics72205002590$121 (Total acquisition cost of Atorvastatin Calcium 80 MG Tablet 90.000 EA, page 9 of the report PDF)$425 (Total estimated savings of Atorvastatin Calcium 80 MG Tablet 90.000 EA, page 9 of the report PDF)1 (Hospitals that named Atorvastatin Calcium 80 MG Tablet 90.000 EA, page 9 of the report PDF)
Sertraline HCl 100 MG Tablet 30.000 EACentral Nervous System Agents - Antidepressants65862001330$115 (Total acquisition cost of Sertraline HCl 100 MG Tablet 30.000 EA, page 9 of the report PDF)$291 (Total estimated savings of Sertraline HCl 100 MG Tablet 30.000 EA, page 9 of the report PDF)1 (Hospitals that named Sertraline HCl 100 MG Tablet 30.000 EA, page 9 of the report PDF)
Omeprazole 20 MG Capsule Delayed Release 1000.000 EAGastrointestinal Agents - Ulcer Drugs/Antispasmodics/Anticholinergics68462039610$112 (Total acquisition cost of Omeprazole 20 MG Capsule Delayed Release 1000.000 EA, page 9 of the report PDF)$4,035 (Total estimated savings of Omeprazole 20 MG Capsule Delayed Release 1000.000 EA, page 9 of the report PDF)1 (Hospitals that named Omeprazole 20 MG Capsule Delayed Release 1000.000 EA, page 9 of the report PDF)
Sertraline HCl 50 MG Tablet 500.000 EACentral Nervous System Agents - Antidepressants70010020405$67 (Total acquisition cost of Sertraline HCl 50 MG Tablet 500.000 EA, page 9 of the report PDF)$337 (Total estimated savings of Sertraline HCl 50 MG Tablet 500.000 EA, page 9 of the report PDF)1 (Hospitals that named Sertraline HCl 50 MG Tablet 500.000 EA, page 9 of the report PDF)
Atorvastatin Calcium 20 MG Tablet 500.000 EACardiovascular Agents - Antihyperlipidemics00378395105$56 (Total acquisition cost of Atorvastatin Calcium 20 MG Tablet 500.000 EA, page 9 of the report PDF)$4,755 (Total estimated savings of Atorvastatin Calcium 20 MG Tablet 500.000 EA, page 9 of the report PDF)1 (Hospitals that named Atorvastatin Calcium 20 MG Tablet 500.000 EA, page 9 of the report PDF)
Rivaroxaban 20 MG Tablet 30.000 EAHematological Agents - Anticoagulants50458057930$31 (Total acquisition cost of Rivaroxaban 20 MG Tablet 30.000 EA, page 9 of the report PDF)$46,579 (Total estimated savings of Rivaroxaban 20 MG Tablet 30.000 EA, page 9 of the report PDF)1 (Hospitals that named Rivaroxaban 20 MG Tablet 30.000 EA, page 9 of the report PDF)
Insulin Aspart 100 UNIT/ML Solution 10.000 ML UUEndocrine and Metabolic Agents - Antidiabetics00169750111$16 (Total acquisition cost of Insulin Aspart 100 UNIT/ML Solution 10.000 ML UU, page 9 of the report PDF)$12,099 (Total estimated savings of Insulin Aspart 100 UNIT/ML Solution 10.000 ML UU, page 9 of the report PDF)1 (Hospitals that named Insulin Aspart 100 UNIT/ML Solution 10.000 ML UU, page 9 of the report PDF)

Drug names, classes and NDCs are the report's own words. Select a column heading to sort. Back to top

The hospitals

The report names the 27 hospitals that sent data. On pages 10 to 25 each one describes, in its own words, the programs and services its 340B savings fund. ClinX lists the hospitals and links to those pages. It does not transcribe the descriptions, which also state figures about each hospital.

  • Bridgton Hospital
  • Calais Community Hospital
  • Central Maine Medical Center
  • Down East Community Hospital
  • Houlton Regional Hospital
  • MaineGeneral Medical Center
  • MaineHealth Franklin Hospital
  • MaineHealth Lincoln Hospital
  • MaineHealth Maine Medical Center
  • MaineHealth Pen Bay Hospital
  • MaineHealth Stephens Hospital
  • MaineHealth Waldo Hospital
  • Millinocket Regional Hospital
  • Mount Desert Island Hospital
  • Northern Light A.R. Gould Hospital
  • Northern Light Blue Hill Hospital
  • Northern Light Charles A. Dean Hospital
  • Northern Light Eastern Maine Medical Center
  • Northern Light Maine Coast Hospital
  • Northern Light Mayo Hospital
  • Northern Light Mercy Hospital
  • Northern Light Sebasticook Valley Hospital
  • Northern Maine Medical Center
  • Penobscot Valley Hospital
  • Redington-Fairview General Hospital
  • Rumford Hospital
  • St. Mary’s Regional Medical Center

Read the descriptions, pages 10 to 25

The hospitals are in the order the report's pages print them.

Read it with care. These are totals the state published, and the two dollar totals are rounded as the report prints them. The report is the State's summary of what the hospitals sent. The hospitals' own filings are not in this dataset, so the totals cannot be checked against them.

A drug appears in a table only when some hospital named it among its three. The tables are not a list of every drug the hospitals bought or dispensed. A drug that no hospital placed among its three is not listed.

No measure is calculated for Maine. The other states' measures are worked out for each filer, and this report has one set of figures for the whole state. So Maine's figures are shown as the state printed them, and the states are not added together or compared. Methods sets out each calculation.

Where the figures come from

Hospitals report each year to the Maine Health Data Organization. The law has the organization post a summary report. It does not have the organization post each hospital's report.

Report PDF
Open the report on the Maine Health Data Organization's website
Title
1st Annual 340B Drug Program Transparency Report, April 2, 2026
Period
fiscal year 2024
SHA-256
5129748fe1a704a2bf458c331c5ccb129306f14d90380964e0f7dfbf0fd3c442
Retrieved
16 November 2026
Pages used
3 to 25 of 26